Schering-Plough

Volastra Therapeutics Appoints David Nicholson, Ph.D., to Board of Directors

Retrieved on: 
Monday, November 6, 2023
Biotechnology, Health, Genetics, Pharmaceutical, Oncology, EVP, Bayer, Pembrolizumab, Chairperson, PD-1, Merck, Schering-Plough, Research, University, Cancer, Therapy, University of Wales, Newport, Patient, Doctor of Philosophy, Pharmaceutical industry, Volastra, Organon, Pharmacology

Volastra Therapeutics , a clinical-stage cancer biotechnology company, today announced the appointment of David Nicholson, Ph.D., as an independent member of its Board of Directors.

Key Points: 
  • Volastra Therapeutics , a clinical-stage cancer biotechnology company, today announced the appointment of David Nicholson, Ph.D., as an independent member of its Board of Directors.
  • Nicholson joins our board as the company is moving expeditiously through the clinic with two novel, differentiated oral KIF18A inhibitors, as well as a pipeline of synthetic lethal and immune-activating assets,” said Sandi Peterson, Chair of the Board.
  • Dr. Nicholson most recently served as EVP and Global Head of Research and Development at Allergan Pharmaceuticals.
  • Dr. Nicholson currently serves as the Chair of the Board of Exscientia, a world-leading artificial intelligence company focused on immunology, immuno-oncology and oncology.

Axsome Therapeutics Appoints Dr. Sue Mahony to its Board of Directors

Retrieved on: 
Wednesday, October 11, 2023
Aston, Eli Lilly and Company, Acquisition, Doctor of Philosophy, Amgen, Drug development, Business, London School of Management Education, Central nervous system, MD, Organization, University, Mahony, Patient, Chordoma, Therapy, CSL Limited, Schering-Plough, Marketing, Master of Business Administration, Business administration, CNS, CSL Vifor, Horizon Therapeutics, London School of Business and Finance, Pharmaceutical industry, Management, Pharmacy, Philosophy, Lilly, Science

Dr. Mahony most recently served on the board of directors of Horizon Therapeutics from 2019 until its acquisition by Amgen in October 2023.

Key Points: 
  • Dr. Mahony most recently served on the board of directors of Horizon Therapeutics from 2019 until its acquisition by Amgen in October 2023.
  • “We are pleased to welcome Dr. Mahony, who has extensive leadership experience in global drug development and commercialization, to our board of directors,” said Herriot Tabuteau, MD, Chief Executive Officer of Axsome.
  • Dr. Mahony served on the board of directors of Vifor Pharma from 2019 until its acquisition by CSL Limited in 2022.
  • Dr. Mahony also serves on the board of directors of the Chordoma Foundation, a nonprofit dedicated to improving the lives of people affected by chordoma.

VMX 2024 KICKS OFF NEW YEAR AT PREEMINENT ANNUAL GLOBAL VETERINARY CONFERENCE

Retrieved on: 
Wednesday, October 4, 2023
Well, World's fair, The Show of Shows, Orange County Convention Center, CE, OCCC, Workflow, CAE, Schitt's Creek, The New York Times, Veterinary medicine, ChatGPT, Manatee, Expo Hall, Rehabilitation, Creek, Prime (liturgy), Implementation, Boehringer Ingelheim, Human bonding, Organization, Schering-Plough, Future, Area studies, Student, The Things, Emmy Awards, Animal, Patient, American Veterinary Medical Association, VMX, AI, Veterinarian, DVM, BluePearl Specialty and Emergency Pet Hospital, Video game, Music, Medical device

ORLANDO, Fla., Oct. 4, 2023 /PRNewswire/ -- Following record-breaking attendance at the 2023 Veterinary Meeting & Expo (VMX), the North American Veterinary Community (NAVC) will host its 41st annual conference Jan. 13-17, 2024 in Orlando, FL at the Orange County Convention Center (OCCC) and everywhere virtually. As the veterinary industry's first conference of the year, VMX sets the direction for veterinary medicine annually and provides the veterinary industry's first continuing education, scientific sessions and hands-on workshops led by world-renowned veterinary leaders. More than 580 companies and organizations from around the world will showcase the latest in animal healthcare products, diagnostics and more in the award-winning Expo Hall. This year's "Show of Shows'' theme will introduce a World's Fair-like experience featuring food, entertainment, events and activities. It will also feature headlining entertainment including singer/songwriter Tyler Hubbard and Emmy-Award-winning actor and director Dan Levy.

Key Points: 
  • As the veterinary industry's first conference of the year, VMX sets the direction for veterinary medicine annually and provides the veterinary industry's first continuing education, scientific sessions and hands-on workshops led by world-renowned veterinary leaders.
  • As the veterinary industry's first conference of the year, VMX sets the direction for veterinary medicine annually.
  • "VMX is where the global veterinary industry gathers each year to learn the latest in veterinary medicine and where life-saving new products and innovations are introduced to the industry.
  • Veterinary and veterinary nurse/technician students, as always, may attend for free, and guest registration is also available.

Athersys Director Jane Wasman Appointed Board Chair

Retrieved on: 
Monday, October 2, 2023
Health, Other Science, Research, Pharmaceutical, Science, Biotechnology, International, Shareholder, General counsel, Schering-Plough, Stroke, Harvard Law School, Princeton University, Associate, Acorda Therapeutics, Açorda, Regenerative medicine, Organization, SLS, JD, Chairperson, Therapy, Management

Current Director Jane Wasman, JD, has been appointed Board Chair, effective September 28, 2023.

Key Points: 
  • Current Director Jane Wasman, JD, has been appointed Board Chair, effective September 28, 2023.
  • Ms. Wasman has served as a Director of the Company since November 2020, currently serving as Chair of Athersys’ Audit Committee and previously serving as Chair of its Nominations, Governance & Compliance Committee.
  • “We are delighted that Jane will now be chairing Athersys’ board.
  • “On behalf of the Athersys Board of Directors and the company’s employees, I am honored to assume the responsibilities of Board Chair and to help guide our various initiatives to drive shareholder value,” said Ms. Wasman.

NAVC and MentorVet Partner To Provide Veterinary Nurses/Technicians Access to New Approach to Mentorship

Retrieved on: 
Thursday, September 28, 2023
Partnership, BS, Education, Veterinary medicine, Research, Mentorship, MS, Schering-Plough, CQD, Hive, Nursing, Risk, American Veterinary Medical Association, Mental health, CVT, DVM

ORLANDO, Fla., Sept. 28, 2023 /PRNewswire/ -- The North American Veterinary Community (NAVC) announces its support of MentorVet Tech, a new program created by MentorVet that is redefining veterinary mentorship with a holistic approach to helping veterinary nurses/technicians thrive in every aspect of their career. MentorVet and the NAVC are partnering to offer an extension of the MentorVet Tech program to veterinary nurses and technicians with multiple flash mentorship sessions. These interactive 90-minute sessions will be provided for no additional cost during NAVC's HiVE Vet Nurse + Tech event October 16-18 in Austin, TX, and facilitated by the MentorVet Team.

Key Points: 
  • MentorVet and the NAVC are partnering to offer an extension of the MentorVet Tech program to veterinary nurses and technicians with multiple flash mentorship sessions.
  • "The NAVC is pleased to partner with MentorVet to help reach, recruit, and engage veterinary nurses and technicians to be part of this program," said NAVC CEO, Gene O'Neill.
  • "The NAVC is pleased to partner with MentorVet to help reach, recruit, and engage veterinary nurses and technicians to be part of this program," said NAVC CEO, Gene O'Neill.
  • MentorVet Tech was developed by Addie Reinhard, DVM, MS, mental health professionals, and expert veterinary technicians including MentorVet Tech program director, Alyssa Mages, BS, CVT.

OnKure Therapeutics Appoints Ann Howell, Pharm.D., as Vice President of Regulatory Affairs

Retrieved on: 
Wednesday, September 20, 2023
University, Schering-Plough, Pharming, Pharmacovigilance, NDA, Cancer, Novo Nordisk, Attention, Rutgers University, AML, Forma, Acquisition, Olutasidenib, Patient, Forest Laboratories, Entrepreneurship, Regulatory affairs, FDA, Medical device

BOULDER, Colo., Sept. 20, 2023 (GLOBE NEWSWIRE) -- OnKure, Inc., a clinical-stage biopharmaceutical company discovering and developing the next generation of oncology precision medicines, today announced the appointment of Ann Howell as Vice President of Regulatory Affairs.

Key Points: 
  • BOULDER, Colo., Sept. 20, 2023 (GLOBE NEWSWIRE) -- OnKure, Inc., a clinical-stage biopharmaceutical company discovering and developing the next generation of oncology precision medicines, today announced the appointment of Ann Howell as Vice President of Regulatory Affairs.
  • Dr. Howell brings an abundance of experience managing regulatory affairs activities for both small and large biopharmaceutical companies, with global regulatory responsibilities across a variety of therapeutic areas, including oncology.
  • “We are delighted to welcome Ann to the OnKure team,” said Tony Piscopio, Ph.D., Co-Founder, President and Chief Executive Officer of OnKure.
  • “Ann has an impressive background in leading the regulatory strategies for numerous product developments and subsequent NDA submissions, in addition to expertise overseeing global regulatory interactions for oncology development projects.

AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors

Retrieved on: 
Monday, September 18, 2023
Partnership, Therapy, Schering-Plough, Foreign Affairs Policy Board, Marketing, Overalls, State university system, Atopic dermatitis, Inflammation, Genentech, Acquisition, SAN, Rhône-Poulenc, Biology, Galenica, Johnson & Johnson, Health, Rheumatoid arthritis, Financial adviser, Pharmaceutical industry, Management, New York University, Rutgers University

“We are excited to welcome John to Anaptys’ Board of Directors as chairman.

Key Points: 
  • “We are excited to welcome John to Anaptys’ Board of Directors as chairman.
  • With more than 25 years of diverse experience across the biopharmaceutical landscape, John brings a track record of substantial accomplishment across our sector as a biotech CEO and Board member.
  • During this tenure, he has overseen the evolution of AnaptysBio from an early-stage antibody generation platform to a clinical-stage organization.
  • “It has been an honor to serve on this dynamic Board of Directors.

IR-MED Appoints Richard Serbin, Esq. to its Advisory Board

Retrieved on: 
Wednesday, September 13, 2023
Bachelor of Science in Nursing, Interim, Wayne State University Law School, Schering-Plough, Veterinary medicine, Biotechnology, McNeil, Senior advisor, Ethicon, Advisory board, Serbin, Rutgers University, New York University School of Law, Dermatology, Revlon, Disease, Rutgers University College, Johnson & Johnson, Seton Hall University School of Law, FDA, Female, Bradley Pharmaceuticals, Pharmaceutical industry, Science, Pharmacy

He held senior management roles at Johnson & Johnson and served on the Board of Directors of numerous Johnson & Johnson subsidiary companies including Ethicon, Ortho, Johnson & Johnson Consumer Products, Pittman-Moore, McNeil and Johnson & Johnson Development Corporation, that company’s strategic venture capital division.

Key Points: 
  • He held senior management roles at Johnson & Johnson and served on the Board of Directors of numerous Johnson & Johnson subsidiary companies including Ethicon, Ortho, Johnson & Johnson Consumer Products, Pittman-Moore, McNeil and Johnson & Johnson Development Corporation, that company’s strategic venture capital division.
  • He formerly served as Chief Operating Officer of the Gorlin Companies and he served as President of Bradley Pharmaceuticals.
  • degree from Seton Hall Law School, and a Master’s Degree in Trade Regulations and Law from New York University Law School.
  • I’m pleased to join the company’s Advisory Board and contribute to its momentum toward bringing innovative, cost-effective, noninvasive solutions to market.”
    “We welcome Richard to our Advisory Board.

RayzeBio Appoints Christy Oliger to its Board of Directors

Retrieved on: 
Tuesday, August 29, 2023
Biotechnology, Health, Radiology, Pharmaceutical, Oncology, GSK, University, Senior, Radionuclide, Schering-Plough, Genentech, Cancer, Roche, Economics, Dermatology, Retirement, Patient, Growth, Santa Barbara, Rare, Neurology, Fine chemical, Medical imaging

RayzeBio, Inc., a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, appointed Christy Oliger to its board of directors.

Key Points: 
  • RayzeBio, Inc., a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, appointed Christy Oliger to its board of directors.
  • I look forward to working with RayzeBio’s accomplished management team on the company’s next phase of growth,” said Ms. Oliger.
  • “I am delighted to welcome Christy to our board of directors.
  • Previously, Ms. Oliger also served on the board of Sierra Oncology, Inc. which was acquired by GSK for $1.9 billion.

Global Veterinary Vaccines Market 2023-2029: Merck & Co. Dominates the Competition, Closely Followed by Boehringer Ingelheim, Ceva Sante Animale, and Zoetis

Retrieved on: 
Wednesday, August 23, 2023
Benchmark, Vaccine, Antigen, Partnership, Vaccination, Marketing, Veterinarian, Aquaculture, Livestock, Infection, Uniloc USA, Inc. v. Microsoft Corp., Iowa State University, Infant, Compound annual growth rate, Schering-Plough, Air Liquide, Ceva, Acquisition, Animal, Artemis Technologies, Dog, Cattle, Rabbit, Growth, Merck, Merck & Co., Enrofloxacin, Health, Pig, Virbac, Disease, Boehringer Ingelheim Animal Health, Bordetella bronchiseptica, Cat, Fine chemical, Pharmaceutical industry, Pet

To maintain a competitive edge and meet changing demands, market participants are employing various strategies, such as acquisitions and partnerships.

Key Points: 
  • To maintain a competitive edge and meet changing demands, market participants are employing various strategies, such as acquisitions and partnerships.
  • In terms of market competition, Merck & Co., Inc. emerged as a forerunner in the market, closely followed by companies like Boehringer Ingelheim International GmbH, Ceva Sante Animale, and Zoetis Inc.
  • Apr-2022: Ceva Sante Animale signed an agreement with Mitsui & Co., Ltd., a Japan-based investment, and trading company to form Ceva Bussan Animal Health K.K.
  • This Joint venture aims to boost the broadening of the veterinary laboratory to Japan, a critical market for the business.